lymphoma

(redirected from B-cell lymphoma)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
Related to B-cell lymphoma: DLBCL
  • noun

Words related to lymphoma

a neoplasm of lymph tissue that is usually malignant

References in periodicals archive ?
Diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma (NHL), is a cancer of the immune system that is usually aggressive and marked by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow, or other organs.
These data suggest that the role of Zevalin in the treatment of diffuse large B-cell lymphoma should be considered in first-line treatment.
Global Markets Direct's, 'Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2012', provides an overview of the Diffuse Large B-Cell Lymphoma therapeutic pipeline.
Primary mediastinal (thymic) large B-cell lymphoma usually presents as a bulky lesion in the anterior-superior mediastinum.
The purpose of the trial is to evaluate how B-cell lymphoma cells respond to the new agent, how patients tolerate the treatment and how long patients can live with the treatment without the disease becoming worse.
Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma (NHL) accounting for up to 30 percent of newly diagnosed cases.
Chief, Division of Oncology, at Stanford University and Principal Investigator on this trial said, "Non-Hodgkin's B-cell lymphoma typically exhibits a slow growth rate and excellent initial response to current treatments.
Nobody really understands why AIDS-associated cases of B-cell lymphoma have popped up with increasing frequency.
Global Markets Direct's, 'Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2012', provides an overview of the Diffuse Large B-Cell Lymphoma therapeutic pipeline.
T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is an aggressive non-Hodgkin lymphoma with a male predominance.
Its target differs from the antibody marketed for the treatment of non-Hodgkin's B-cell lymphoma, which binds to the CD20 antigen.
Sidman of the Jackson Laboratory in Bar Harbor has discovered four specific steps in the development of B-cell lymphoma -- a cancer of the immune system -- that occur in mice after activation of a cancer-triggering gene, or oncogene.
T-cell lymphoma; lymphomatoid papulosis; primary cutaneous follicle center lymphoma; primary cutaneous marginal zone B-cell lymphoma; and primary cutaneous diffuse large B-cell lymphoma, leg type.
The tumor-specific responses shown by patients with low-grade follicular B-cell lymphoma indicate that idiotypic vaccines used may reduce or eliminate cancer cells that remain following conventional therapies.
Full browser ?